A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044
NCT ID: NCT05539651
Last Updated: 2024-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
72 participants
INTERVENTIONAL
2022-11-10
2024-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RBD5044 SAD experimental group
Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD5044 on Day 1.
RBD5044
Subcutaneously Administered RBD5044 in Healthy Subjects
RBD5044 MAD experimental group
Subjects in MAD experimental groups will receive one subcutaneous injection of RBD5044 on Day 1 and another subcutaneous injection of RBD5044 on Day 29.
RBD5044
Subcutaneously Administered RBD5044 in Healthy Subjects
Placebo SAD group
Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.
Placebo
Subcutaneously Administered Placebo in Healthy Subjects
Placebo MAD group
Subjects in MAD placebo groups will receive one subcutaneous injection of placebo on Day 1 and another subcutaneous injection of placebo on Day 29.
Placebo
Subcutaneously Administered Placebo in Healthy Subjects
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RBD5044
Subcutaneously Administered RBD5044 in Healthy Subjects
Placebo
Subcutaneously Administered Placebo in Healthy Subjects
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent.
2. Male and female subjects, aged 18 to 65 years (inclusive).
3. Body mass index between 18 and 32 kg/m2, inclusive.
4. Fasting TG ≥ 0.9 mmol/L (80 mg/dL) and ≤ 3.4 mmol/L (300 mg/dL) at screening.
5. Fasting LDL-C \< 4.9 mmol/L (\<190 mg/dL) at screening.
6. Healthy as determined by pre-study medical history, physical examination, clinical laboratory assessments, and 12-lead electrocardiogram (ECG).
7. Satisfy one of the following:
* Females: must be non-pregnant and non-lactating; surgically sterile, post-menopausal, abstinent, or if engaged in sexual relations of child-bearing potential, the subject is using an acceptable contraceptive method (refer to Section 4.6.3) for four weeks before, during, and for at least 6 months after the last dose of study drug administration.
* Males: must be surgically sterile, abstinent, or if engaged in sexual relations of child-bearing potential, the subject is utilizing an acceptable contraceptive method (refer to Section 4.6.3)) during and for at least 6 months after the last dose of study drug administration.
8. Non-smokers and non-nicotine users for at least 90 days before screening
Exclusion Criteria
2. History or presence of cardiovascular disease (including peripheral artery and cerebrovascular disease).
3. Systolic blood pressure (SBP) \> 140 mmHg and/or diastolic blood pressure (DBP) \> 90 mmHg after 10 minutes of supine rest, unless determined by the investigator to be not clinically relevant.
4. Diagnosis of diabetes mellitus.
5. Received any medication or nutraceutical to alter serum lipids within 30 days before screening.
6. Active serious mental illness or psychiatric disorder, including but not limited to schizophrenia, bipolar disorder, or severe depression, which require current pharmacological intervention.
7. Alanine aminotransferase (ALT) and/or total bilirubin are above the upper limit of normal reference range (ULN); no investigator discretion and repeat assessments are allowed.
8. Aspartate aminotransferase (AST), alkaline phosphatase (ALP), or gamma-glutamyl transferase (GGT) \> 2 × ULN (no investigator discretion); or, if AST, ALP, or GGT \> ULN, but ≤ 2 × ULN and considered clinically relevant by the investigator.
9. Used prescription drugs within 14 days or 7 half-lives (whichever is longer) before the first dose of study drug.
10. Used over-the-counter medication, excluding routine vitamins, within 7 days before the first dose of the study drug, unless determined by the investigator to be not clinically relevant, and unlikely to impact blood lipids level.
11. Received an investigational product within 30 days or 7 half-lives (whichever is longer) before the first dose of the study drug or are in the follow-up of another clinical study. If subjects used advanced therapy (ASO/siRNA/gene therapy/cell therapy), it should be judged by the investigator.
12. Hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), syphilis infection, or positive hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus antibody (HCVAb), HIV antibody (HIVAb), treponema pallidum antibody (TP-Ab) at screening.
13. Clinically significant illness within 7 days before the first dose of the study drug.
14. Consume more than 14 (female) or 21 (male) units of alcohol per week (unit: 1 glass of wine \[125 mL\] = 1 measure of spirits = ½ pint of beer) within the 12 months before screening or positive screen for alcohol abuse.
15. History or clinical evidence of drug abuse within the 12 months before screening or positive screen for drug abuse. Drug abuse is defined as compulsive, repetitive, and/or chronic use of drugs or other substances with or without problems related to their use and/or where stopping or a dose reduction will lead to withdrawal symptoms.
16. Donated more than 500 mL of blood within 90 days before the first dose of the study drug.
17. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-acetylgalactosamine (GalNAc).
18. History of intolerance to subcutaneous (SC) injection or relevant abdominal scarring (surgical, burns, etc.).
19. Any conditions which would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study in the opinion of the investigator.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Suzhou Ribo Life Science Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Q-Pharm Pty Limited
Brisbane, , Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RBAP1101
Identifier Type: -
Identifier Source: org_study_id